Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

INTRODUCTION: Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinical trials and a real-world setting on efficacy, tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Meca-Lallana, José E., Prieto González, José M., Caminero Rodríguez, Ana B., Olascoaga Urtaza, Javier, Alonso, Ana M., Durán Ferreras, Eduardo, Espinosa, Raúl, Dotor, Julio, Romera, Mercedes, Ares Luque, Adrián, Pérez Ruiz, Domingo, Calles, Carmen, Hernández, Miguel A., Hervás García, Miguel, Mendoza Rodríguez, Amelia, Berdei Montero, Yasmina, Téllez, Nieves, Herrera Varó, Nicolás, Sotoca, Javier, Presas-Rodríguez, Silvia, Querol Gutierrez, Luis A., Hervás Pujol, Mariona, Batlle Nadal, Jordi, Martín Ozaeta, Gisela, Gubieras Lillo, Laura, Martínez Yélamos, Sergio, Ramió-Torrentà, Lluís, Mallada Frechin, Javier, Belenguer Benavides, Antonio, Gascón-Giménez, Francisco, Casanova, Bonaventura, Landete Pascual, Lamberto, Berenguer, Leticia, Navarro, Laura, Gómez Gutierrez, Montserrat, Durán, Carmen, Rodríguez Regal, Ana, Álvarez, Elena, García-Estévez, Daniel A., López Real, Ana M., Llaneza González, Miguel A., Marzo Sola, María E., Sánchez-Menoyo, José L., Oterino, Agustín, Villaverde González, Ramón, Castillo-Triviño, Tamara, Álvarez de Arcaya, Amaya, Llarena, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630277/
https://www.ncbi.nlm.nih.gov/pubmed/37861931
http://dx.doi.org/10.1007/s40120-023-00557-7

Ejemplares similares

Ejemplares similares